Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia

SHANGHAI,July 28,2021 -- Eccogene,Inc.,a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics,announced the initiation of a Phase 1a clinical trial evaluating ECC0509,an oral inhibitor of semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1),as a potentially novel therapy for patients with non-alcoholic steatohepatitis (NASH) and osteoarthritis (OA) associated pain.

The trial is a Phase 1,randomized,double-blind,placebo-controlled,sequential single- and multiple ascending dose clinical trial to evaluate the safety,pharmacokinetics,pharmacodynamics of ECC0509 in healthy volunteers. All participants will receive either placebo,or a single dose or multiple doses of ECC0509. Preliminary topline data from the clinical trial is expected in Q1 2022.

About ECC0509

ECC0509 is a highly selective and peripherally distributed small molecule inhibitor of SSAO/VAP-1,elevated activity of which is associated with pathophysiology of human disorders including NASH and OA. In Eccogene non-clinical studies,ECC0509 was shown to be well-absorbed,safe at the anticipated human dose range,and efficacious in animal models of NASH and OA pain following oral administration.

About Eccogene

Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally.The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases.

Contacts for Eccogene

contact@eccogene.com

www.eccogene.com